Recent Research Analysts’ Ratings Updates for Penumbra (PEN)

Penumbra (NYSE: PEN) recently received a number of ratings updates from brokerages and research firms:

• 1/17/2026 – Penumbra was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 1/16/2026 – Penumbra was downgraded by analysts at Leerink Partners to a “market perform” rating.
• 1/16/2026 – Penumbra had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $374.00 price target on the stock, up previously from $345.00.
• 1/16/2026 – Penumbra had its “market perform” rating reaffirmed by analysts at Leerink Partners. They now have a $374.00 price target on the stock.
• 1/16/2026 – Penumbra was downgraded by analysts at Truist Financial Corporation from a “buy” rating to a “hold” rating. They now have a $374.00 price target on the stock, up previously from $370.00.
• 1/16/2026 – Penumbra was downgraded by analysts at Baird R W from a “strong-buy” rating to a “hold” rating.
• 1/16/2026 – Penumbra was downgraded by analysts at Needham & Company LLC from a “buy” rating to a “hold” rating.
• 1/15/2026 – Penumbra was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating. They now have a $349.00 price target on the stock.
• 1/15/2026 – Penumbra was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $374.00 price target on the stock, up previously from $350.00.
• 1/15/2026 – Penumbra had its “equal weight” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $374.00 price target on the stock.
• 1/15/2026 – Penumbra was downgraded by analysts at William Blair from an “outperform” rating to a “market perform” rating.
• 1/15/2026 – Penumbra was downgraded by analysts at Piper Sandler from an “overweight” rating to a “hold” rating. They now have a $374.00 price target on the stock.
• 1/15/2026 – Penumbra was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 1/15/2026 – Penumbra was downgraded by analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating. They now have a $374.00 price target on the stock.
• 1/5/2026 – Penumbra had its “outperform” rating reaffirmed by analysts at Evercore ISI. They now have a $340.00 price target on the stock.
• 1/5/2026 – Penumbra had its price target raised by analysts at Bank of America Corporation from $320.00 to $370.00. They now have a “buy” rating on the stock.
• 12/29/2025 – Penumbra had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Penumbra had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/20/2025 – Penumbra was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/18/2025 – Penumbra had its price target raised by analysts at Truist Financial Corporation from $312.00 to $370.00. They now have a “buy” rating on the stock.
• 12/18/2025 – Penumbra was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating. They now have a $370.00 price target on the stock, up previously from $275.00.
• 12/17/2025 – Penumbra had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $355.00 price target on the stock.
• 12/17/2025 – Penumbra had its price target raised by analysts at Canaccord Genuity Group Inc. from $355.00 to $359.00. They now have a “buy” rating on the stock.
• 12/17/2025 – Penumbra had its price target raised by analysts at Needham & Company LLC from $326.00 to $388.00. They now have a “buy” rating on the stock.
• 12/16/2025 – Penumbra was given a new $345.00 price target on by analysts at Robert W. Baird.
• 12/15/2025 – Penumbra had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/11/2025 – Penumbra was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $350.00 price target on the stock, up previously from $285.00.
• 12/8/2025 – Penumbra had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Penumbra had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.

Insiders Place Their Bets

In other news, Director Harpreet Grewal sold 186 shares of the firm’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $227.58, for a total transaction of $42,329.88. Following the completion of the sale, the director owned 8,516 shares in the company, valued at approximately $1,938,071.28. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Thomas Wilder sold 186 shares of Penumbra stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $310.72, for a total transaction of $57,793.92. The disclosure for this sale is available in the SEC filing. Insiders sold 34,144 shares of company stock worth $10,260,127 in the last three months. 4.20% of the stock is owned by corporate insiders.

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.